- AM-101 has potential to be first-ever approved therapy for tinnitus
- Top-line results from first of two Phase 3 trials expected in August
ZUG, Switzerland, June 7, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage
company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, will host a breakfast
meeting focused on the treatment of acute inner ear tinnitus and AM-101's Phase 3 clinical development program. The event will take
place from 8 am to 9:30 am EDT on Tuesday, June 14, 2016, in New York City. The meeting will feature a presentation by Hinrich
Staecker, MD, PhD, who serves as a principal investigator in the Company's TACTT2 trial, as well as presentations by members of the
Auris Medical leadership team.
This event will be held for investors and research analysts. To reserve a seat, please contact Cindy McGee via
e-mail at investors@aurismedical.com. A live webcast will be available through the Events and
Presentations page in the Investors section of the Auris Medical website at www.aurismedical.com, and a replay of the presentation will be available following the
event.
Hinrich Staecker, MD, PhD, completed medical school at the Albert Einstein College of Medicine with distinction in
Otology Research. After completing his residency in otolaryngology at Montefiore Medical Center, Dr. Staecker went on to a
fellowship in Otology and Neurotology at Harvard Medical School's Massachusetts Eye and Ear. He is dual board certified in
Otolaryngology and Neurotology by the American Board of Otolaryngology. Currently, Dr. Staecker is the David and Mary Zamierowsky
Professor at University of Kansas School of Medicine, a member of the Collegium Oto-Rhino-Laryngologica, a fellow of the
Triological Society, and a member of the American Otological Society.
The AM-101 Phase 3 clinical development program includes the TACTT2 and TACTT3 trials. The TACTT2 trial has
enrolled more than 330 patients and is being conducted primarily in North America under a Special Protocol Assessment (SPA) with
the US Food and Drug Administration. Top-line results from this trial are expected in August 2016. The TACTT3 trial is being
conducted in Europe, and enrollment of approximately 630 patients (300 in the acute stage and 330 in the post-acute stage) is
expected to be completed by the end of June 2016. Top-line results from this trial are expected in the fourth quarter of 2016.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important
unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear
tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel
formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003
and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global
Market under the symbol "EARS."
Forward-looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical fact and may include statements that address future operating, financial or business performance
or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as
"may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential,"
"outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business
decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not
limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris
Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property
position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual
Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the
date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future
developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their
entirety by this cautionary statement.
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, investors@aurismedical.com
HUG#2018338
